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Gene Delivery to the Rat Liver Using
Cationic Lipid Emulsion/DNA Complex:
Comparison between Intra-arterial,
Intraportal and Intravenous Administration
Objective: To compare the efficiency of intra-arterial, intraportal, and intra-
venous administration of cationic lipid emulsion/DNA complex, as used for gene
transfer to rat liver.
Materials and Methods: DNA-carrier complex for the in-vivo experiment was
prepared by mixing DNA and a cationic lipid emulsion. According to the adminis-
tration route used (intra-arterial, intraportal, or intravenous), the animals were
assigned to one of three groups. The heart, lung, liver, spleen and kidneys were
removed and assayed for total protein and luciferase concentration.
Results: The cationic lipid emulsion/DNA complex used successfully transfect-
ed the various organs via the different administration routes employed. Luciferase
activity in each organ of untreated animals was negligible. Liver luciferase values
were significantly higher in the groups in which intra-arterial or intraportal admin-
istration was used.
Conclusion: The intra-arterial or intraportal administration of cationic lipid
emulsion/DNA complex is superior to intravenous administration and allows
selective gene transfer to the liver.
ene transfer into experimental animals or humans resulting in generalized
or tissue-specific expression may allow precise in-vivo manipulation of
biological processes to cure diseases and induce immune responses to
pathogens (1, 2). The basic challenge in gene therapy is to develop approaches to the
delivery of genetic material to appropriate cells in a way that is specific, efficient, and
safe.
Continuous efforts have been applied to the development of gene delivery systems
known as vectors, which encapsulate the gene and guide it to the target cell. Viruses
are ideal vectors, being naturally suited to the highly efficient transfection of genetic
material to cells. The use of viral vectors is, however, limited by safety concerns relat-
ed to the immune and inflammatory responses they trigger and immune rejection phe-
nomena arising due to repeated administration (1, 3, 4). As an alternative to viral vec-
tors, various non-viral gene delivery systems, including cationic lipids, cationic poly-
mers, and naked DNA, have been prepared for use in gene therapy.
In liver-directed gene therapy involving radiologists, approach routes may include
direct percutaneous injection, and transcatheter intra-arterial or intraportal administra-
tion. In the case of viral vectors, it has been reported that intra-arterial administration
is more efficient than intravenous administration (5), though cationic lipid vectors
have not been compared in this way.
The purpose of this study was to compare the efficiency of intra-arterial, intraportal,
and intravenous administration of cationic lipid emulsion/DNA complex, as used for
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Ggene transfer to rat liver.
MATERIALS AND METHODS
Preparation of Cationic Lipid Emulsion
The emulsion we used contained 100  L/mL oil (squa-
lene) and lipid emulsifiers [1, 2-dioleyl-sn-glycro-3-
trimethylammonium-propane (DOTAP), and 1, 2-dioleyl-
sn-glycro-3-phosphoethanolamine (DOPE), combined in a
ratio of 5:1 by weight], and was prepared as described pre-
viously (6). Briefly, lipid emulsifiers were weighed and dis-
persed in water, and the resulting mixture was sonicated in
an ice/water bath using a probe type sonicator (high inten-
sity ultrasonic processor, 600 W model; Sonic and
Materials, Danbury, Conn., U.S.A.). The lipid solution was
added to oil, and the mixture was sonicated further in an
ice/water bath. Prior to use, the cationic lipid emulsion
thus prepared was kept at 4 , and its short-term stability
was monitored by measuring the time-dependant ab-
sorbance changes occurring at 600 nm. The average size of
emulsion particle was 164.5 nm.
Preparation of Plasmid DNA
As reporter genes, we used pCMV-Luc+ and pCMV- .
The latter, encoding Escherichia coli (E. coli) l acZ ( -
galactosidase) gene expression plasmid driven by the hu-
man cytomegalovirus immediate-early promoter, was sup-
plied by Clontech Laboratories (Palo Alto, Cal., U.S.A.),
and the pCMV-Luc, consisting of the cytosolic form of
Phontinus pyralis luciferase cDNA, was obtained from
pGL3 (Promega, Madison, Wis., U.S.A.) using Xba I and
Hind III restriction and was subcloned into the plasmid
pcDNA3.1 (Invitrogen, Seoul, Korea). Both plasmids were
amplified in the E. coli DH5- strain and purified using a
Qiagen mega-kit (Qiagen Inc., Chatsworth, Cal., U.S.A.),
according to the manufacturer’s instructions. The purity of
the DNA used (OD260/OD280 1.8 ) was determined by
agarose gel electrophoresis and the measurement of optical
density.
Animal Studies
To prepare DNA-carrier complexes for this experiment,
20  g of pCMV-Luc+ and the carrier, the amount of which
corresponded to the weight ratio between cationic lipid in
the lipid formulation and DNA in the complex that showed
the maximum transfection efficiency, were diluted with 0.5
mL of DMEM (Dulbecco’s modified Eagle’s medium) solu-
tion and mixed by inversion. The total volume of the mix-
ture was 1 mL, and the time interval between mixing and
infusion was minimized.
Twenty-four 8-week-old Sprague-Dawley rats, each
weighing 200-300 gms, were used in this study; their hous-
ing and the procedure employed were in accordance with
the National Institutes of Health guidelines. The animals
were divided into three groups according to whether injec-
tion was performed intra-arterially (n=9), intraportally
(n=8), or intravenously (n=7). Three other rats which did
not undergo treatment were included as negative controls.
The animals were anesthetized in an ether jar prior to
the injection of a 1:1 mixture of xylazine hydrochloride
(Rompun; Bayer Korea, Seoul, Korea) and ketamine hy-
drochloride (Ketara; Yuhan Yanghang, Seoul, Korea) into
the peritoneal cavity. Those in which administration was
intra-arterial or intraportal were prepared for surgery, and
a midline ventral incision was made. The liver was then re-
tracted and connective tissues were cleared to visualize the
gastroduodenal artery or mesenteric veins. For intra-arteri-
al administration, the gastroduodenal artery was exposed
and cannulated with a 28-G needle, and the DNA-carrier
complex was slowly injected into the proper hepatic artery
at a rate of 1 mL/min. The catheter was then removed and
the gastroduodenal artery was ligated; the abdominal inci-
sion was sutured using the continuous interlocking method.
For intraportal administration, a tributary of the superior
mesenteric vein was selected, a 28-G needle was posi-
tioned in it and secured, and the DNA-carrier complex was
delivered at the same rate as previously. The catheter was
removed and the catheterized vein ligated, and the abdom-
inal incision was closed in the same manner as before. For
intravenous administration, the DNA-carrier complex was
injected into the vein of the tail using a 24-G catheter,
which was subsequently slowly flushed with saline and re-
moved.
Luciferase Activity Assay
Two rats in Group II, in which administration was intra-
portal, expired prior to sacrifice. The remaining 22 rats sur-
vived and were sacrificed 24 hours after the procedure.
The heart, lung, liver, spleen and kidneys were removed
from each animal and underwent , separately, high-speed
homogenization using T-25-Ultra-Turrax homogenizer
(Janke & Kunkel GmbH, KG, Germany) and, for each col-
lected organ, 5  l/mg of pH 7.8 lysis buffer comprising 0.1
M Tris-HCl, 2 mM EDTA and 0.1% Triton X-100. After
two freeze/thaw cycles, the homogenized organ lysates
were centrifuged for 10 mins at 4 and at 12,000 rpm in
an Eppendorf centrifuge. A portion of the supernatants
was assayed for protein concentration using a Bio-Rad pro-
tein assay kit (Bio-Rad Laboratories, Hercules, Cal.,
U.S.A.). Luciferase activity in the lysates was quantified
using a Promega kit (Madison, Wis., U.S.A.) with a lumi-
nometer (Turner Designs Luminometer, Model TD-20/20;
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onds at room temperature, and the luciferase count was
calculated from relative light units using a standard curve
obtained from purified firefly luciferase (Sigma). The lu-
ciferase count of each organ in each rat was tabulated, and
intra-arterial, intraportal, and intravenous administration
were compared in terms of the efficiency with which they
facilitated gene transfer to the liver.
For all groups, mean values and standard deviations of
luciferase enzyme activity were calculated, and using
Wilcoxon’s rank sum test, the statistical significance of dif-
ferences in enzyme activity between the different routes of
administration was determined.
RESULTS
The amount of luciferase enzyme in each organ, which
varied according to the route of administration of the
cationic lipid emulsion/DNA complex, is summarized in
Table 1 and Figure 1. In groups I and II, luciferase activity
was highest in the liver (22.94 and 115.21 pg/mg protein,
respectively), but in group III, it was highest in the spleen
(5.94 pg/mg protein). Luciferase activity in each organ of
untreated animals was negligible. Luciferase values in the
liver were significantly higher in groups I and II than in
groups III (p = 0.0080 and 0.0034, respectively), though
between groups I and II there was no significant difference
(p = 1.0).
DISCUSSION
Since the liver is the site of many metabolic diseases and
malignancies, it is an organ in which gene therapy may be
particularly valuable. The potential indications for liver-di-
rected gene therapy include inherited liver disorders such
as familial hypercholesterolemia (7) and ornithine transcar-
bamylase deficiency (8); inherited systemic disorders in-
cluding hemophilia (9); viral hepatitis, liver tumors, allo-
graft or xenograft rejection, and ischemia/reperfusion in-
jury (10), and are expanding continuously.
The availability of both the intravenous approach and lo-
cal delivery routes is another important reason why the
liver has been a model organ in the development of gene
transfer technology. Except for recombinant adenoviruses
and a few vectors with targeting moiety for hepatocytes,
most viral and non-viral vectors are not liver specific. To
achieve efficient delivery, these vectors have been injected
into the liver or peritoneal cavity; infused into the portal
vein or hepatic artery; or instilled into the bile duct. The
purposes of local administration of vectors are to limit their
transgenic expression in the liver and to enhance the effi-
ciency of transfection. In an experimental study using a re-
combinant adenovirus encoding wild-type p53 or  -galac-
tosidase, intra-arterial delivery increased the transgenic ex-
pression in tumor tissue and decreased systemic exposure
in comparison with intravenous delivery (5). In murine liv-
er metastases, tumors showed significantly higher trans-
genic expression after portal venous or intraperitoneal
virus administration (11).
There are two kinds of cationic lipid-based gene delivery
systems, namely liposome and emulsion. A cationic lipo-
some is a closed double layer of cationic lipids filled with
water. It is positively charged and interacts with negatively
charged DNA molecules to form a stable complex.
Cationic liposomes have been used widely in gene transfer
both in vitro and in vivo (12). The oil-in-water emulsion
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Table 1. Average and Standard Deviation of the Amount of Luciferase Enzyme (expressed in pg/mg protein) in Each Organ of
the Three Groups of Rats [Intra-arterial (IA), Intraportal (IP), and Intravenous (IV) Administration]
Route of Administration Heart Lung Liver Spleen Kidney
IA (Group I) 2.31 3.32 0.76 1.74 22.94 35.64 3.90 2.20 0.65 1.07
IP (Group II)  2.72 3.18 0.44 0.66 115.21 227.03 1.10 1.82 0.83 1.36
IV (Group III)  1.48 3.90 0.93 1.45 0.70 1.86 5.94 9.48 0.00 0.00
Untreated controls 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fig.1. The graph illustrates average and standard deviation of the
amount of luciferase enzyme in each organ of the three groups
which underwent, respectively, intra-arterial (IA), intraportal (IP),
and intravenous (IV) administration.used consists of oil dispersed in the aqueous phase with a
suitable emulsifying agent such as a phospholipid or non-
ionic surfactant. The use of cationic lipid emulsions as gene
delivery vectors has not, however, been widely investigat-
ed.
Cationic lipid-mediated gene delivery is not yet as effi-
cient as the use of a viral vector. Although intravenously-
injected liposomes have an intrinsic affinity for the liver,
the uptake of liposomes by this organ in the absence of a
targeting mechanism is highly variable (13 15), and most
liposomal carriers lose their ability to transfer DNA in the
presence of 10% serum (12, 16, 17). Because of the
physical instability of the liposome/DNA complex and the
inactivation of complexes by negatively charged molecules
in serum, its transfection efficiency has been found to be
relatively low compared with that of viral vectors (18, 19).
To enhance efficiency, a new formulation offering serum
stability and a strategy for local administration is therefore
needed.
To overcome the problems associated with liposomes,
castor oil emulsions have been introduced as alternative
gene transfer vectors (12); new cationic lipid emulsions use
squalene or soybean oil as a core lipid (20). It has been
shown that in the presence of serum, the use of a cationic
lipid emulsion/DNA complex has led to efficient cell trans-
fection (6). In in-vitro transfection assay of this complex,
more than 60% of transfection efficiency was retained in
the presence of up to 90% serum (6). Unlike liposomal car-
riers, cationic lipid emulsion retained its physical integrity
while forming a complex with DNA. In-vitro DNA release
tests have shown that binding of the emulsion/DNA com-
plex was strong, and it was thus unaffected by the anionic
polyion, poly-L-aspartic acid (16). In-vivo, this stable
emulsion system delivered genes to endothelial cells in the
mouse nasal cavity more efficiently than the commercially
available liposomes, Lipofectamine and Lipofectin (4).
We conducted this animal experiment to determine
whether local delivery of a cationic lipid emulsion/DNA
complex through the hepatic artery or portal vein is advan-
tageous, and our results clearly showed that intra-arterial
or intraportal administration is superior to intravenous ad-
ministration.
Several important issues in cationic lipid-mediated gene
delivery await solution. For example, the distribution of li-
posomal vectors to various organs, and the efficiency with
which this is achieved, are affected by factors which in-
clude liposome/DNA complex particle size (21 22). The
use of a cationic lipid emulsion for gene transfection has
not been thoroughly investigated, though it has been
shown that after its intravenous administration, gene ex-
pression in the lung is usually higher than in the spleen and
other organs (23). In our study, on the other hand, lu-
ciferase activity in the lung was quite low, probably be-
cause of the stability of the complex used in the experi-
ment. Further investigation of the biodistribution of lipid
emulsion in each specific organ is, however, required. In
hepatic gene delivery, the optimal particle size of a lipo-
some or emulsion, for example, may differ according to
whether administration is intra-arterial or intraportal, or
intravenous, and research into this is also needed. As a fur-
ther example, the liver contains cell types which include
hepatocytes, Kupffer cells, endothelial cells and various tu-
mor cells, and in hepatic gene therapy, target cells can vary
according to the disease being treated. In metabolic dis-
eases, the primary target is hepatocytes, while in hepatic
tumors, gene expression in tumor cells should be maxi-
mized and gene delivery to normal parenchyma mini-
mized. In clinical or experimental studies using various dif-
ferent vectors, a clear understanding of exactly where
transgenic expression should occur is therefore important.
Because the majority of liposomes administered intra-
venously are endocytosed by the reticuloendothelial sys-
tem (15, 17), the reduction of Kupffer cell uptake and en-
hancement of hepatocyte or tumor uptake are further chal-
lenges faced by research into liposome targeting.
To enhance targeted gene delivery, lipid carriers can be
modified (24): polyethylene glycol conjugate or ligands for
receptors, for example, can be incorporated into lipid carri-
ers. An amphipathic polyethylene glycol such as Tween 80
can provide a steric barrier, as well as increasing the hy-
drophilicity of the liposome surface, both of which may re-
duce interaction between the liposome and plasma pro-
teins and their recognition and uptake by macrophages of
the reticuloendothelial system (25). Hepatocytes have gly-
cosyl receptors on their surface, and the hepatic uptake of
glycosylated liposome can be enhanced by receptor-medi-
ated endocytosis. Other ligands for receptors under investi-
gation include lactose, transferrin, and antibodies. A recent
report described selective gene expression in hepatic VX2
carcinoma after intra-arterial delivery of the DNA/lipo-
some/transferrin complex (26). The hemodynamic charac-
teristics of this and other hepatic tumors are quite different
from those of normal liver parenchyma: while normal he-
patocytes, for example, receive blood primarily from the
portal vein, the hepatic artery supplies nearly all the blood
required by a hepatic malignancy. Because of these hemo-
dynamic differences, the optimal conditions for lipid carri-
ers may differ according to the target cells involved (hepa-
tocytes or hepatic malignancies).
Although local delivery of a cationic lipid emulsion/DNA
complex via the hepatic artery or portal vein increases he-
patic transgenic expression, it may also maximize the he-
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patic toxicity of the complex. Where the emulsion is used
clinically, the hepatic toxicity of its therapeutic dose should
therefore be investigated.
In conclusion, our findings show that in hepatic gene
transfer, intra-arterial or intraportal delivery of a cationic
lipid emulsion/DNA complex was superior to systemic de-
livery. Further investigation of the effect of surface modifi-
cations, the optimal conditions for the delivery route and
target cells, and the hepatic toxicity of the emulsion is war-
ranted.
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